# Rob Etherington

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rob-etherington
Canonical HTML page: https://getbiobrief.com/entity/rob-etherington

## Timeline

- **2026-08-14**: Q2 2026 financial results reported — Laser Photonics reports net sales of $1.8 million and positive gross margin; Zeo reports 23% sequential revenue growth; Clene reports Q2 results and CNM-Au8 program updates.
- **2026-06-30**: Q2 2026 reporting period ends — Laser Photonics, Zeo Energy, and Clene complete the second quarter ended June 30, 2026.
- **2026-05**: FDA meeting minutes confirm accelerated approval pathway for CNM-Au8 — Clene receives formal meeting minutes stating its proposed NfL data may be capable of supporting an NDA for CNM-Au8 in ALS under accelerated approval.

## Recent coverage (1 stories)

### Clene's CNM-Au8 ALS NDA Path Advances with Survival Data from 2 Phase 2 Trials
2026-08-15 01:53:22 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Clene Inc. reports FDA meeting minutes confirm an accelerated approval pathway for CNM-Au8 in ALS. New biomarker analyses link NfL stabilization to longer survival and improved function. The company plans to submit an NDA, citing data from two completed Phase 2 trials.
Full story: https://getbiobrief.com/story/clene-cnm-au8-als-nda-q2-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.